Small Molecule Drug Discovery for Neglected Tropical Snakebite
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These inhibitors have a number of advantages over current antivenom therapies including better peripheral tissue distribution, higher shelf stability, a higher safety profile, the ability for pre-hospital oral or topical administration, and greater affordability (55).”
From Assessing Target Specificity of the Small Molecule Inhibitor MARIMASTAT to Snake Venom Toxins: A Novel Application of Thermal Proteome Profiling (2024) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ultra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998
Causes and Consequences of Snake Venom Variation
Casewell, N. R., Jackson, T. N. W., Laustsen, A. H., & Sunagar, K. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.05.006 · Cited by 396
Self-citationGutiérrez, J. M., Lewin, M. R., Williams, D. J., & Lomonte, B. (2020) · Toxins · doi:10.3390/toxins12020131 · Cited by 92
Research works printed but not linked: 82
- Hotez, 2009, Rescuing the bottom billion through control of neglected tropical diseases, Lancet, 373, 1570, 10.1016/S0140-6736(09)60233-6 · DOI · Paper page
- Bodimeade, 2019, Neglected tropical diseases: elimination and eradication, Clin. Med. (Lond), 19, 157, 10.7861/clinmedicine.19-2-157 · doi:10.7861/clinmedicine.19-2-157
- De Rycker, 2018, Challenges and recent progress in drug discovery for tropical diseases, Nature, 559, 498, 10.1038/s41586-018-0327-4 · DOI · Paper page
- Molyneux, 2017, The London Declaration on Neglected Tropical Diseases: 5 years on, Trans. R. Soc. Trop. Med. Hyg., 375, 239
- Gutiérrez, 2017, Snakebite envenoming, Nat. Rev. Dis. Primers, 3, 17063, 10.1038/nrdp.2017.63 · DOI · Paper page
- Kasturiratne, 2008, The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths, PLoS Med., 5, 10.1371/journal.pmed.0050218 · DOI · Paper page
- Longbottom, 2018, Vulnerability to snakebite envenoming: a global mapping of hotspots, Lancet, 392, 673, 10.1016/S0140-6736(18)31224-8 · DOI · Paper page
- Harrison, 2009, Snake envenoming: a disease of poverty, PLoS Negl. Trop. Dis., 3, e569, 10.1371/journal.pntd.0000569 · DOI · Paper page
- Harrison, 2019, The time is now: a call for action to translate recent momentum on tackling tropical snakebite into sustained benefit for victims, Trans. R. Soc. Trop. Med. Hyg., 113, 834, 10.1093/trstmh/try134 · DOI
- Williams, 2019, Strategy for a globally coordinated response to a priority neglected tropical disease: snakebite envenoming, PLoS Negl. Trop. Dis., 13, 12, 10.1371/journal.pntd.0007059 · DOI · Paper page
- The Lancet, 2019, Snakebite – emerging from the shadows of neglect, Lancet, 393, 2175, 10.1016/S0140-6736(19)31232-2 · doi:10.1016/s0140-6736(19)31232-2
- Tasoulis, 2017, A review and database of snake venom proteomes, Toxins (Basel), 9, 290, 10.3390/toxins9090290 · DOI · Paper page
- Slagboom, 2017, Haemotoxic snake venoms: their functional activity, impact on snakebite victims and pharmaceutical promise, Br. J. Haematol., 177, 947, 10.1111/bjh.14591 · DOI · Paper page
- Ferraz, 2019, Multifunctional toxins in snake venoms and therapeutic implications: from pain to hemorrhage and necrosis, Front. Ecol. Evol., 7, 218, 10.3389/fevo.2019.00218 · DOI · Paper page
- Gutiérrez, 2016, Hemorrhage caused by snake venom metalloproteinases: a journey of discovery and understanding, Toxins (Basel), 8, 93, 10.3390/toxins8040093 · DOI · Paper page
- Ranawaka, 2013, Neurotoxicity in snakebite – the limits of our knowledge, PLoS Negl. Trop. Dis., 7, 10.1371/journal.pntd.0002302 · DOI · Paper page
- de Silva, 2016, Adverse reactions to snake antivenom, and their prevention and treatment, Br. J. Clin. Pharmacol., 81, 446, 10.1111/bcp.12739 · DOI · Paper page
- Lalloo, 2003, Snake antivenoms, J. Toxicol. Clin. Toxicol., 41, 277, 10.1081/CLT-120021113 · DOI · Paper page
- Harrison, 2017, Preclinical antivenom-efficacy testing reveals potentially disturbing deficiencies of snakebite treatment capability in East Africa, PLoS Negl. Trop. Dis., 11, 10.1371/journal.pntd.0005969 · DOI
- Brown, 2012, Consequences of neglect: analysis of the sub-Saharan African snake antivenom market and the global context, PLoS Negl. Trop. Dis., 6, 10.1371/journal.pntd.0001670 · doi:10.1371/journal.pntd.0001670
- Laustsen, 2017, Recombinant snakebite antivenoms: a cost-competitive solution to a neglected tropical disease?, PLoS Negl. Trop. Dis., 11, 10.1371/journal.pntd.0005361 · DOI
- Laustsen, 2019, How can monoclonal antibodies be harnessed against neglected tropical diseases and other infectious diseases?, Expert Opin. Drug Discov., 14, 1103, 10.1080/17460441.2019.1646723 · DOI
- Lewin, 2016, Varespladib (LY315920) appears to be a potent, broad-spectrum, inhibitor of snake venom phospholipase A2 and a possible pre-referral treatment for envenomation, Toxins (Basel), 8, 248, 10.3390/toxins8090248 · DOI · Paper page
- Wang, 2018, Exploration of the inhibitory potential of varespladib for snakebite envenomation, Molecules, 23, 391, 10.3390/molecules23020391 · DOI · Paper page
- Layfield, 2020, Repurposing cancer drugs batimastat and marimastat to inhibit the activity of a group I metalloprotease from the venom of the western diamondback rattlesnake, Crotalus atrox, Toxins (Basel), 12, 309, 10.3390/toxins12050309 · DOI · Paper page
- Albulescu, 2020, Preclinical validation of a repurposed metal chelator as a community-based therapeutic for hemotoxic snakebite, Sci. Transl. Med., 12, 10.1126/scitranslmed.aay8314 · DOI · Paper page
- Xie, 2020, Neutralizing effects of small molecule inhibitors and metal chelators on coagulopathic Viperinae snake venom toxins, Biomedicines, 8, 297, 10.3390/biomedicines8090297 · DOI
- Bulfone, 2018, Developing small molecule therapeutics for the initial and adjunctive treatment of snakebite, J. Trop. Med., 2018, 4320175, 10.1155/2018/4320175 · DOI · Paper page
- Albulescu, 2020, A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite, Nat. Commun., 11, 6094, 10.1038/s41467-020-19981-6 · DOI · Paper page
- Williams, 2010, The Global Snake Bite Initiative: an antidote for snake bite, Lancet, 375, 89, 10.1016/S0140-6736(09)61159-4 · DOI · Paper page
- Williams, 2019, The urgent need to develop novel strategies for the diagnosis and treatment of snakebites, Toxins (Basel), 11, 363, 10.3390/toxins11060363 · DOI
- Benson, 2019, Topical and transdermal drug delivery: from simple potions to smart technologies, Curr. Drug Deliv., 16, 444, 10.2174/1567201816666190201143457 · DOI · Paper page
- Nicholls, 2014, Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial, JAMA, 311, 252, 10.1001/jama.2013.282836 · DOI · Paper page
- Bryan-Quirós, 2019, Neutralizing properties of LY315920 toward snake venom group I and II myotoxic phospholipases A2, Toxicon, 157, 1, 10.1016/j.toxicon.2018.11.292 · DOI · Paper page
- Lewin, 2018, Delayed LY333013 (oral) and LY315920 (intravenous) reverse severe neurotoxicity and rescue juvenile pigs from lethal doses of Micrurus fulvius (eastern coral snake) venom, Toxins (Basel), 10, 479, 10.3390/toxins10110479 · DOI · Paper page
- Lewin, 2018, Delayed oral LY333013 rescues mice from highly neurotoxic, lethal doses of Papuan taipan (Oxyuranus scutellatus) venom, Toxins (Basel), 10, 380, 10.3390/toxins10100380 · DOI · Paper page
- Bittenbinder, 2018, Coagulotoxic cobras: clinical implications of strong anticoagulant actions of African spitting Naja venoms that are not neutralised by antivenom but are by LY315920 (varespladib), Toxins (Basel), 10, 516, 10.3390/toxins10120516 · DOI · Paper page
- Winer, 2018, Matrix metalloproteinase inhibitors in cancer therapy: turning past failures into future successes, Mol. Cancer Ther., 17, 1147, 10.1158/1535-7163.MCT-17-0646 · DOI · Paper page
- Huxley-Jones, 2007, The evolution of the vertebrate metzincins; insights from Ciona intestinalis and Danio rerio, BMC Evol. Biol., 7, 63, 10.1186/1471-2148-7-63 · DOI
- Arias, 2017, Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom, Toxicon, 132, 40, 10.1016/j.toxicon.2017.04.001 · DOI · Paper page
- Rucavado, 2000, Inhibition of local hemorrhage and dermonecrosis induced by Bothrops asper snake venom: effectiveness of early in situ administration of the peptidomimetic metalloproteinase inhibitor batimastat and the chelating agent CaNa2EDTA, Am. J. Trop. Med. Hyg., 63, 313, 10.4269/ajtmh.2000.63.313 · DOI · Paper page
- Howes, 2007, Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators, Toxicon, 49, 734, 10.1016/j.toxicon.2006.11.020 · DOI
- Xie, 2020, Antivenom neutralization of coagulopathic snake venom toxins assessed by bioactivity profiling using nanofractionation analytics, Toxins (Basel), 12, 53, 10.3390/toxins12010053 · DOI
- Ainsworth, 2020, An analysis of preclinical efficacy testing of antivenoms for sub-Saharan Africa: inadequate independent scrutiny and poor-quality reporting are barriers to improving snakebite treatment and management, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008579 · DOI
- Knudsen, 2020, Novel snakebite therapeutics must be tested in appropriate rescue models to robustly assess their preclinical efficacy, Toxins (Basel), 12, 528, 10.3390/toxins12090528 · DOI
- Bhaumik, 2020, Interventions for the management of snakebite envenoming: an overview of systematic reviews, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008727 · DOI
- Still, 2017, Multipurpose HTS coagulation analysis: assay development and assessment of coagulopathic snake venoms, Toxins (Basel), 9, 382, 10.3390/toxins9120382 · DOI
- Still, 2020, Development of high-throughput screening assays for profiling snake venom phospholipase A2 activity after chromatographic fractionation, Toxicon, 184, 28, 10.1016/j.toxicon.2020.05.022 · DOI
- Zdenek, 2019, A taxon-specific and high-throughput method for measuring ligand binding to nicotinic acetylcholine receptors, Toxins (Basel), 11, 600, 10.3390/toxins11100600 · DOI
- Papapetropoulos, 2018, Inventing new therapies without reinventing the wheel: the power of drug repurposing, Br. J. Pharmacol., 175, 165, 10.1111/bph.14081 · DOI
- Janes, 2018, The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis, Proc. Natl. Acad. Sci. U. S. A., 115, 10750, 10.1073/pnas.1810137115 · DOI
- Salvador, 2019, Structural basis for phospholipase A2-like toxin inhibition by the synthetic compound varespladib (LY315920), Sci. Rep., 9, 17203, 10.1038/s41598-019-53755-5 · DOI · Paper page
- Lewin, 2013, Reversal of experimental paralysis in a human by intranasal neostigmine aerosol suggests a novel approach to the early treatment of neurotoxic envenomation, Clin. Case Rep, 1, 7, 10.1002/ccr3.3 · doi:10.1002/ccr3.3
- Lynagh, 2020, Peptide inhibitors of the α-cobratoxin–nicotinic acetylcholine receptor interaction, J. Med. Chem., 63, 13709, 10.1021/acs.jmedchem.0c01202 · DOI
- Albulescu, 2019, A decoy-receptor approach using nicotinic acetylcholine receptor mimics reveals their potential as novel therapeutics against neurotoxic snakebite, Front. Pharmacol., 10, 848, 10.3389/fphar.2019.00848 · DOI
- Lim, 2019, Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method, Sci. Rep., 9, 16727, 10.1038/s41598-019-53216-z · DOI
- Clark, 2013, Technological and sociological advances in HTS: evolution and revolution?, Eur. Pharm. Rev., 18, 55
- Burrows, 2014, The role of modern drug discovery in the fight against neglected and tropical diseases, Medchemcomm, 5, 688, 10.1039/c4md00011k · DOI
- Taylor, 2019, Preclinical development of an oral anti-Wolbachia macrolide drug for the treatment of lymphatic filariasis and onchocerciasis, Sci. Transl. Med., 11, 10.1126/scitranslmed.aau2086 · DOI
- von Geldern, 2019, Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity, PLoS Negl. Trop. Dis., 13, 10.1371/journal.pntd.0007159 · DOI
- Gustavsen, 2018, For as long as necessary: examining 30 years of MSD’s focus on achieving elimination of onchocerciasis and lymphatic filariasis, Int. Health, 10, i3, 10.1093/inthealth/ihx038 · doi:10.1093/inthealth/ihx038
- Boller, 2020, SnakeMap: four years of experience with a national small animal snake envenomation registry, Aust. Vet. J., 98, 442, 10.1111/avj.12993 · doi:10.1111/avj.12993
- Martins, 2019, Snakebite and its impact in rural communities: the need for a One Health approach, PLoS Negl. Trop. Dis., 13
- Turner, 2020, Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis?, Vet. Parasitol., 279, 109057, 10.1016/j.vetpar.2020.109057 · DOI
- Guagliardo, 2020, Guinea worm in domestic dogs in Chad: a description and analysis of surveillance data, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008207 · doi:10.1371/journal.pntd.0008207
- Schioldann, 2018, Why snakebite patients in Myanmar seek traditional healers despite availability of biomedical care at hospitals? Community perspectives on reasons, PLoS Negl. Trop. Dis., 12, 10.1371/journal.pntd.0006299 · DOI
- Corley, 2016, The role of nurses and community health workers in confronting neglected tropical diseases in sub-Saharan Africa: a systematic review, PLoS Negl. Trop. Dis., 10, 10.1371/journal.pntd.0004914 · DOI
- Aird, 2017, Coralsnake venomics: analyses of venom gland transcriptomes and proteomes of six Brazilian taxa, Toxins (Basel), 9, 187, 10.3390/toxins9060187 · DOI
- Tan, 2018, Venom proteomics and antivenom neutralization for the Chinese eastern Russell’s viper, Daboia siamensis from Guangxi and Taiwan, Sci. Rep., 8, 8545, 10.1038/s41598-018-25955-y · DOI
- Theakston, 2000, Crisis in snake antivenom supply for Africa, Lancet, 356, 2104, 10.1016/S0140-6736(05)74319-1 · DOI · Paper page
- Schiermeier, 2015, Africa braced for snakebite crisis, Nature, 525, 299, 10.1038/525299a · DOI
- Habib, 2020, Challenges and prospects of snake antivenom supply in sub-Saharan Africa, PLoS Negl. Trop. Dis., 14, 10.1371/journal.pntd.0008374 · DOI
- Potet, 2019, Reviewing evidence of the clinical effectiveness of commercially available antivenoms in sub-Saharan Africa identifies the need for a multi-centre, multi-antivenom clinical trial, PLoS Negl. Trop. Dis., 13, 10.1371/journal.pntd.0007551 · DOI
- Visser, 2008, Failure of a new antivenom to treat Echis ocellatus snake bite in rural Ghana: the importance of quality surveillance, Trans. R. Soc. Trop. Med. Hyg., 102, 445, 10.1016/j.trstmh.2007.11.006 · DOI
- Warrell, 2008, Unscrupulous marketing of snake bite antivenoms in Africa and Papua New Guinea: choosing the right product – ‘What’s in a name?, Trans. R. Soc. Trop. Med. Hyg., 102, 397, 10.1016/j.trstmh.2007.12.005 · doi:10.1016/j.trstmh.2007.12.005
- Alirol, 2015, Antivenoms for snakebite envenoming: what is in the research pipeline?, PLoS Negl. Trop. Dis., 9, 10.1371/journal.pntd.0003896 · DOI
- Taylor, 2014, Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis, Parasitology, 141, 119, 10.1017/S0031182013001108 · DOI · Paper page
- James, 2018, Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, Lancet, 392, 1789, 10.1016/S0140-6736(18)32279-7 · DOI · Paper page
- Boussinesq, 2018, Alternative treatment strategies to accelerate the elimination of onchocerciasis, Int. Health, 10, i40, 10.1093/inthealth/ihx054 · DOI · Paper page
- Hong, 2019, AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis, Proc. Natl. Acad. Sci. U. S. A., 116, 1414, 10.1073/pnas.1816585116 · DOI
- Johnston, 2017, Identification and prioritization of novel anti-Wolbachia chemotypes from screening a 10,000-compound diversity library, Sci. Adv., 3, 10.1126/sciadv.aao1551 · DOI
- Clare, 2019, Industrial scale high-throughput screening delivers multiple fast acting macrofilaricides, Nat. Commun., 10, 11, 10.1038/s41467-018-07826-2 · DOI
Cited by
Hall, S. R., Rasmussen, S. A., Crittenden, E., Dawson, C. A., Bartlett, K. E., Westhorpe, A. P., Albulescu, L.-O., Kool, J., Gutiérrez, J. M., & Casewell, N. R. (2023) · Nature Communications · doi:10.1038/s41467-023-43510-w · Cited by 63
“ANOVA statistics for individual statistically analysed graphs are: (a) F(3,8) = 1.”
Self-citationCarter, R. W., Gerardo, C. J., Samuel, S. P., Kumar, S., Kotehal, S. D., Mukherjee, P. P., Shirazi, F. M., Akpunonu, P. D., Bammigatti, C., Bhalla, A., et al. (2022) · Toxins · doi:10.3390/toxins15010022 · Cited by 39
Smith, C. F., Modahl, C. M., Ceja Galindo, D., Larson, K. Y., Maroney, S. P., Bahrabadi, L., Brandehoff, N. P., Perry, B. W., McCabe, M. C., Petras, D., et al. (2024) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2024.100779 · Cited by 11
Metadata
- Authors
- Clare, R. H., Hall, S. R., Patel, R. N., & Casewell, N. R.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2021-05
- Volume
- 42
- Issue
- 5
- Pages
- 340-353
- ISSN
- 0165-6147
- Cited by
- 76
- References
- 3
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- Medical Research Council (MR/S00016X/1, 200517/Z/16/Z)
- Liverpool School of Tropical Medicine
- Wellcome Trust (204806/Z/16/Z)
- Royal Society (NIF\R1\192161)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Small Molecule Drug Discovery for Neglected Tropical Snakebite. https://app.cochat.ai/papers/10.1016/j.tips.2021.02.005
- The paper
- Clare, R. H., Hall, S. R., Patel, R. N., & Casewell, N. R. (2021). Small Molecule Drug Discovery for Neglected Tropical Snakebite. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2021.02.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.